Winfield Associates’s Anixa Biosciences ANIX Stock Holding History

Winfield Associates’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-80	Closed	–	–	832
2017 Q3	$0	Hold	80	–	–	﹤0.01%	789
2017 Q2	$0	Hold	80	–	–	﹤0.01%	869
2017 Q1	$0	Hold	80	–	–	﹤0.01%	750
2016 Q4	$0	Hold	80	–	–	﹤0.01%	724
2016 Q3	$0	Hold	80	–	–	﹤0.01%	693
2016 Q2	$0	Hold	80	–	–	﹤0.01%	705
2016 Q1	$0	Hold	80	–	–	﹤0.01%	688
2015 Q4	$0	Buy	+80	New	+$281	﹤0.01%	304

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DIA

Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CAM

Concorde Asset Management Ann Arbor, Michigan $204M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Winfield Associates's ANIX Position: Q4 2017 in Review

Winfield Associates sold out of Anixa Biosciences (ANIX) in Q4 2017, closing a stake of 80 shares.

Winfield Associates first reported a position in ANIX in Q4 2015 and held it in 8 quarters. The position peaked at $0 in Q3 2017. 18 funds tracked by Wall St. Rank hold ANIX as of Q4 2017.

Winfield Associates reported no remaining Anixa Biosciences position as of Q4 2017 after selling out during the quarter.
Winfield Associates sold 80 Anixa Biosciences shares in Q4 2017.
Winfield Associates first reported a position in Anixa Biosciences in Q4 2015 and held it in 8 quarters.
Winfield Associates's Anixa Biosciences position peaked at $0 in Q3 2017.
18 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2017.

Based on Winfield Associates's 13F filing for Q4 2017, filed 12 Feb 2018.